Search

Ritu Kaushik

from Summit, NJ
Get Report
Connected to:
Anju Kaushik, 50Arvind B Kaushik, 48Asha M Kaushik, 58Devesh Kaushik, 31Kaushik R Kaushik, 63Leia Kaushik, 41Medha Kaushik, 39Prakash Kaushik, 39Praveen Kaushik, 48Sachin Kaushik, 43

Ritu Kaushik Phones & Addresses

  • Summit, NJ
  • Springfield, NJ
  • Long Island City, NY
  • 24 Church St APT 23, Watertown, MA 02472 (617) 744-6247
  • Waltham, MA

Work

Company: Glaxosmithkline Jan 2013 Position: New product development

Education

School / High School: Northeastern University- Boston, MA Jan 2005 Specialities: Research Scientist

Resumes

Resumes

Ritu Kaushik Photo 1

Ritu Kaushik

View page
Ritu Kaushik Photo 2

Ritu Kaushik

View page
Ritu Kaushik Photo 3

Ritu Kaushik

View page
Ritu Kaushik Photo 4

Ritu Kaushik Summit, NJ

View page
Work:
GlaxoSmithKline

Jan 2013 to 2000
New Product Development
Vertex Pharmaceuticals, Inc

Sep 2011 to Dec 2012
Scientist I, Formulation Development
Vertex Pharmaceuticals, Inc

Dec 2007 to Sep 2011
Sr. Scientific Associate, Formulation Development
Sustained Release Group, Amgen Inc
Thousand Oaks, CA
May 2007 to Oct 2007
Senior Associate
Clinlab Staffing
Boston, MA
Jan 2007 to Mar 2007
Scientific Associate II - Material Discovery and Characterization group
Drug Regulatory Affairs
Mumbai, Maharashtra
Mar 2003 to Jun 2004
Officer
Burroughs Wellcome Ltd
Mumbai, Maharashtra
Oct 2001 to Dec 2001
Industrial Job Trainee
Education:
Northeastern University
Boston, MA
Jan 2005 to Dec 2006
Research Scientist
Northeastern University
Boston, MA
Sep 2004 to Dec 2006
Masters in Pharmaceutical Sciences
MET's Institute of Pharmacy
Mumbai, Maharashtra
Mar 1998 to Dec 2002
Bachelor of Pharmaceutical Sciences

Publications

Us Patents

Pharmaceutical Compositions Of 3-(6-(1-(2,2-Difluorobenzo[D][1,3]Dioxol-5-Yl) Cyclopropanecarboxamido)-3-Methylpyridin-2-Yl)Benzoic Acid And Administration Thereof

View page
US Patent:
20110256220, Oct 20, 2011
Filed:
Apr 7, 2011
Appl. No.:
13/081750
Inventors:
Marinus Jacobus Verwijs - Framingham MA, US
Ritu Rohit Kaushik - Watertown MA, US
Irina Nikolaevna Kadiyala - Newton MA, US
Christopher Young - Waltham MA, US
Assignee:
VERTEX PHARMACEUTICALS INCORPORATED - Cambridge MA
International Classification:
A61K 9/28
A61K 47/02
A61K 47/32
A61K 31/443
A61P 25/28
A61P 1/10
A61P 11/06
A61P 1/16
A61P 9/00
A61K 47/38
A61P 3/10
US Classification:
424465, 514781, 514769, 5147727, 514338
Abstract:
A pharmaceutical composition comprising Compound 1, (3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid), and at least one excipient selected from: a filler, a diluent, a disintegrant, a surfactant, a binder, a glidant and a lubricant, the composition being suitable for oral administration to a patient in need thereof to treat a CFTR mediated disease such as Cystic Fibrosis. Methods for treating a patient in need thereof include administering an oral pharmaceutical formulation of Compound 1 to the patient.

Pharmaceutical Compositions Of 3-(6-(1-(2,2-Difluorobenzo[D][1,3]Dioxol-5-Yl) Cyclopropanecarboxamido)-3-Methylpyriodin-2-Yl)Benzoic Acid And Administration Thereof

View page
US Patent:
20130095181, Apr 18, 2013
Filed:
Oct 5, 2012
Appl. No.:
13/646130
Inventors:
VERTEX PHARMACEUTICALS INCORPORATED - CAMBRIDGE MA, US
Ritu Rohit Kaushik - Watertown MA, US
Irina Nikolaevna Kadiyala - Newton MA, US
Christopher Ryan Young - Waltham MA, US
Assignee:
VERTEX PHARMACEUTICALS INCORPORATED - CAMBRIDGE MA
International Classification:
A61K 31/443
A61K 9/28
A61K 45/06
A61K 9/14
US Classification:
424465, 514338, 424400, 514312
Abstract:
A pharmaceutical composition comprising Compound 1, (3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid), and at least one excipient selected from: a filler, a diluent, a disintegrant, a surfactant, a binder, a glidant and a lubricant, the composition being suitable for oral administration to a patient in need thereof to treat a CFTR mediated disease such as Cystic Fibrosis. Methods for treating a patient in need thereof include administering an oral pharmaceutical formulation of Compound 1 to the patient.

Pharmaceutical Compositions And Administrations Thereof

View page
US Patent:
20130131107, May 23, 2013
Filed:
Oct 22, 2012
Appl. No.:
13/657345
Inventors:
Vertex Pharmaceuticals Incorporated - Cambridge MA, US
Tim Edward Alcacio - San Diego CA, US
Sneha G. Arekar - Brighton MA, US
Hayley Marie Binch - Encinitas CA, US
Martyn Curtis Botfield - Concord MA, US
Lev Tyler Dewey Fanning - San Marcos CA, US
Peter Diederik Jan Grootenhuis - San Diego CA, US
Dennis James Hurley - San Marcos CA, US
Steven C. Johnston - Litchfield MA, US
Irina Nikolaevna Kadiyala - Newton MA, US
Ritu Rohit Kaushik - Watertown MA, US
Ali Keshavarz-Shokri - San Diego CA, US
Mariusz Krawiec - Marlborough MA, US
Elaine Chungmin Lee - Cambridge MA, US
Brian Luisi - Mansfield MA, US
Ales Medek - Winchester MA, US
Praveen Mudunuri - Waltham MA, US
Mehdi Numa - San Diego CA, US
Urvi Jagdishbhai Sheth - San Diego CA, US
Alina Silina - San Diego CA, US
Mark Jeffrey Sullivan - Framingham MA, US
Marinus Jacobus Verwijs - Framingham MA, US
Xiaoqing Yang - San Diego CA, US
Christopher Ryan Young - Waltham MA, US
Noreen Tasneem Zaman - Acton MA, US
Beili Zhang - San Diego CA, US
Yuegang Zhang - Wayland MA, US
Gregor Zlokarnik - La Jolla CA, US
Assignee:
Vertex Pharmaceuticals Incorporated - Cambridge MA
International Classification:
A61K 31/47
A61K 31/404
A61K 31/443
US Classification:
514312
Abstract:
The present invention relates to pharmaceutical compositions comprising a compound of Formulas I and II, optionally in combination with a Compound of Formula III and/or a Compound of Formula IV. The invention also relates to solid forms and to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis.

Pharmaceutical Compositions And Administrations Thereof

View page
US Patent:
20130158071, Jun 20, 2013
Filed:
Oct 22, 2012
Appl. No.:
13/657299
Inventors:
Vertex Pharmaceuticals Incorporated - Cambridge MA, US
Tim Edward Alcacio - San Diego CA, US
Hayley Marie Binch - Encinitas CA, US
Martyn Curtis Botfield - Concord MA, US
Lev Tyler Dewey Fanning - San Marcos CA, US
Peter Diederik Jan Grootenhuis - San Diego CA, US
Dennis James Hurley - San Marcos CA, US
Irina Nikolaevna Kadiyala - Newton MA, US
Ritu Rohit Kaushik - Watertown MA, US
Ali Keshavarz-Shokri - San Diego CA, US
Mariusz Krawiec - Marlborough MA, US
Elaine Chungmin Lee - Cambridge MA, US
Brian Luisi - Mansfield MA, US
Ales Medek - Winchester MA, US
Mehdi Numa - San Diego CA, US
Urvi Jagdishbhai Sheth - San Diego CA, US
Alina Silina - San Diego CA, US
Marinus Jacobus Verwijs - Framingham MA, US
Xiaoqing Yang - San Diego CA, US
Christopher Ryan Young - Waltham MA, US
Noreen Tasneem Zaman - Acton MA, US
Beili Zhang - San Diego CA, US
Yuegang Zhang - Wayland MA, US
Gregor Zlokarnik - La Jolla CA, US
Assignee:
Vertex Pharmaceuticals Incorporated - Cambridge MA
International Classification:
A61K 31/4709
A61K 31/404
A61K 31/443
US Classification:
514304, 514312, 435 29
Abstract:
The present invention relates to pharmaceutical compositions comprising a compound of Formula I in combination with one or both of a Compound of Formula II and/or a Compound of Formula III. The invention also relates to solid forms and to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis.

Pharmaceutical Compositions Of 3-(6-(1-(2,2-Difluorobenzo[D][1,3]Dioxol-5-Yl) Cyclopropanecarboxamido)-3-Methylpyridin-2-Yl) Benzoic Acid And Administration Thereof

View page
US Patent:
20200197380, Jun 25, 2020
Filed:
Aug 2, 2019
Appl. No.:
16/530240
Inventors:
- Boston MA, US
Rossitza Gueorguieva Alargova - Brighton MA, US
Ritu Rohit Kaushik - Long Island City NY, US
Irina Nikolaevna Kadiyala - Newton MA, US
Christopher Young - Waltham MA, US
Assignee:
Vertex Pharmaceuticals Incorporated - Boston MA
International Classification:
A61K 31/443
A61K 9/28
C07D 405/14
C07D 405/12
A61K 9/16
C07D 451/02
A61K 9/20
A61K 9/00
A61K 45/06
A61K 9/14
A61K 31/47
Abstract:
A pharmaceutical composition comprising Compound 1, (3-(6-(1-(2,2-difluorobenzo [d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid), and at least one excipient selected from: a filler, a diluent, a disintegrant, a surfactant, a binder, a glidant and a lubricant, the composition being suitable for oral administration to a patient in need thereof to treat a CFTR mediated disease such as Cystic Fibrosis. Methods for treating a patient in need thereof include administering an oral pharmaceutical formulation of Compound 1 to the patient.

Pharmaceutical Compositions Of 3-(6-(1-(2,2-Difluorobenzo[D][1,3]Dioxol-5-Yl) Cyclopropanecarboxamido)-3-Methylpyridin-2-Yl) Benzoic Acid And Administration Thereof

View page
US Patent:
20190070155, Mar 7, 2019
Filed:
Jul 31, 2018
Appl. No.:
16/050029
Inventors:
- Boston MA, US
Rossitza Gueorguieva ALARGOVA - Brighton MA, US
Ritu Rohit KAUSHIK - Long Island City NY, US
Irina Nikolaevna KADIYALA - Newton MA, US
Christopher YOUNG - Waltham MA, US
Assignee:
Vertex Pharmaceuticals Incorporated - Boston MA
International Classification:
A61K 31/443
A61K 9/16
A61K 9/00
A61K 9/20
A61K 31/47
Abstract:
A pharmaceutical composition comprising Compound 1, (3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid), and at least one excipient selected from: a filler, a diluent, a disintegrant, a surfactant, a binder, a glidant and a lubricant, the composition being suitable for oral administration to a patient in need thereof to treat a CFTR mediated disease such as Cystic Fibrosis. Methods for treating a patient in need thereof include administering an oral pharmaceutical formulation of Compound 1 to the patient.

Pharmaceutical Compositions Of 3-(6-(1-(2,2-Difluorobenzo[D][1,3]Dioxol-5-Yl) Cyclopropanecarboxamido)-3-Methylpyridin-2-Yl) Benzoic Acid And Administration Thereof.

View page
US Patent:
20160303096, Oct 20, 2016
Filed:
Jan 19, 2016
Appl. No.:
15/001036
Inventors:
- BOSTON MA, US
ROSSITZA GUEORGUIEVA ALARGOVA - BRIGHTON MA, US
RITU ROHIT KAUSHIK - LONGISLAND CITY NY, US
IRINA NIKOLAEVNA KADIYALA - NEWTON MA, US
CHRISTOPHER YOUNG - WALTHAM MA, US
Assignee:
VERTEX PHARMACEUTICALS INCORPORATED - BOSTON MA
International Classification:
A61K 31/443
A61K 31/47
A61K 9/16
A61K 9/20
A61K 9/00
Abstract:
A pharmaceutical composition comprising Compound 1, (3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid), and at least one excipient selected from: a filler, a diluent, a disintegrant, a surfactant, a binder, a glidant and a lubricant, the composition being suitable for oral administration to a patient in need thereof to treat a CFTR mediated disease such as Cystic Fibrosis. Methods for treating a patient in need thereof include administering an oral pharmaceutical formulation of Compound 1 to the patient.

Pharmaceutical Compositions And Administrations Thereof

View page
US Patent:
20160022664, Jan 28, 2016
Filed:
Feb 23, 2015
Appl. No.:
14/629097
Inventors:
- Boston MA, US
Rossitza Gueorguieva Alargova - Brighton MA, US
Tim Edward Alcacio - San Diego CA, US
Hayley Marie Binch - Encinitas CA, US
Martyn Curtis Botfield - Concord MA, US
Lev Tyler Dewey Fanning - San Marcos CA, US
Peter Diederik Jan Grootenhuis - San Diego CA, US
Dennis James Hurley - San Marcos CA, US
Irina Nikolaevna Kadiyala - Newton MA, US
Ritu Rohit Kaushik - Watertown MA, US
Ali Keshavarz-Shokri - San Diego CA, US
Mariusz Krawiec - Marlborough MA, US
Elaine Chungmin Lee - Arlington MA, US
Brian Luisi - Mansfield MA, US
Ales Medek - Winchester MA, US
Mehdi Numa - San Diego CA, US
Urvi Jagdishbhai Sheth - San Diego CA, US
Alina Silina - San Diego CA, US
Marinus Jacobus Verwijs - Framingham MA, US
Xiaoqing Yang - San Diego CA, US
Christopher Ryan Young - Waltham MA, US
Noreen Tasneem Zaman - Acton MA, US
Beili Zhang - San Diego CA, US
Yuegang Zhang - Wayland MA, US
Gregor Zlokarnik - La Jolla CA, US
International Classification:
A61K 31/4709
A61K 31/404
C12Q 1/34
A61K 31/443
Abstract:
The present invention relates to pharmaceutical compositions comprising a compound of Formula I in combination with one or both of a Compound of Formula II and/or a Compound of Formula III. The invention also relates to solid forms and to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis.
Control profile
Ritu Kaushik from Summit, NJ Get Report